{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:01:04Z","timestamp":1790352064497,"version":"4.1.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:p>Melanotan analogues are increasingly associated with pigmentary adverse effects. We report vitiligo-like depigmentation following melanotan use in a patient with atopic dermatitis and alopecia areata, with repigmentation after discontinuation. This case highlights a paradoxical response and the importance of identifying unregulated peptide use in new-onset depigmentation.<\/jats:p>","DOI":"10.1093\/ced\/llag221","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:44:56Z","timestamp":1779968696000},"page":"1971-1974","source":"Crossref","is-referenced-by-count":0,"title":["Depigmented facial and neck patches following melanotan use in a patient with atopic dermatitis and alopecia areata"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0219-8172","authenticated-orcid":false,"given":"Adaku","family":"Ume","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Dignity Health St. Mary Medical Center , Long Beach, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shae","family":"Chambers","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine , Atlanta, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Worswick","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keck School of Medicine of University of Southern California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026092511025408500_llag221-B1","first-page":"775","article-title":"A review and update on melanocyte stimulating hormone therapy: afamelanotide","volume":"12","author":"Fabrikant","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"2026092511025408500_llag221-B2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2133.2010.10104.x","article-title":"Systemic photoprotection in solar urticaria with \u03b1-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-\u03b1-MSH","volume":"164","author":"Haylett","year":"2011","journal-title":"Br J Dermatol"},{"key":"2026092511025408500_llag221-B3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for erythropoietic protoporphyria","volume":"373","author":"Langendonk","year":"2015","journal-title":"N Engl J Med"},{"key":"2026092511025408500_llag221-B4","doi-asserted-by":"crossref","first-page":"e13012","DOI":"10.1111\/phpp.13012","article-title":"German cohort observational study to investigate the short- and long-term safety and\u00a0clinical effectiveness of afamelanotide 16\u2005mg (SCENESSE) in patients with erythropoietic protoporphyria (EPP)","volume":"41","author":"Homey","year":"2025","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2026092511025408500_llag221-B5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","article-title":"Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial","volume":"151","author":"Lim","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2026092511025408500_llag221-B6","article-title":"Changes of melanocytic lesions induced by melanotan injections and sun bed use in a teenage patient with FAMMM syndrome","volume":"2","author":"Sivyer","year":"2012","journal-title":"Dermatol Pract Concept"},{"key":"2026092511025408500_llag221-B7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s13730-020-00447-z","article-title":"Melanotan II: a possible cause of renal infarction: review of the literature and case report","volume":"9","author":"Peters","year":"2020","journal-title":"CEN Case Rep"},{"key":"2026092511025408500_llag221-B8","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3109\/15563650.2012.740637","article-title":"Melanotan II injection resulting in systemic toxicity and rhabdomyolysis","volume":"50","author":"Nelson","year":"2012","journal-title":"Clin Toxicol (Phila)"},{"key":"2026092511025408500_llag221-B9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000356389","article-title":"Melanoma associated with the use of melanotan-II","volume":"228","author":"Hjuler","year":"2014","journal-title":"Dermatology"},{"key":"2026092511025408500_llag221-B10","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2340\/00015555-1062","article-title":"Pseudoleucoderma after injections of afamelanotide in a patient with atopic dermatitis","volume":"91","author":"von Bartenwerffer","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"2026092511025408500_llag221-B11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdcr.2023.03.025","article-title":"Vitiligo during dupilumab therapy","volume":"36","author":"Picone","year":"2023","journal-title":"JAAD Case Rep"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag221\/68430140\/llag221.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1971\/68430140\/llag221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1971\/68430140\/llag221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:03:07Z","timestamp":1790348587000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/10\/1971\/8697878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5,29]]},"published-print":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag221","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,5,29]]}}}